… The androgen receptor drives the growth of metastatic castration-resistant prostate cancer. …
and in discovering novel therapeutic targets to maximize clinical outcome. However, the …

… observed in prostate cancer, usually at later stages of disease; the clinical significance of …
by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022…

… androgen receptor is indispensable for the prostate … prostate gland but also for the
development of prostatic neoplasms and the progression of PC to CRPC [2]. Therefore, therapeutic …

… Therapeutic interventions for advanced prostate cancer (PCa) are based on the inhibition of
the androgen receptor (AR) … Resistance to androgen deprivation therapy is inevitable, and …

… androgen receptor (AR) independent may develop into neuroendocrine prostate cancer (NEPC)…
These models offer opportunities for studying the mechanisms of AR-variant-driven PCa …

… androgen receptor (AR), a member of the nuclear receptor … prostate gland [1]. The AR is
also involved in the development of … variants in order to find novel therapeutic targets in CRPC. …

… Testosterone suppression by androgen deprivation therapy is the cornerstone of prostate
cancer treatment. New-generation hormone therapies improved overall survival in castration-…

… androgen receptor (AR) is expressed on luminal prostate … The clinical impact of increased
synthesis of this metabolite is yet … is the therapeutic target of AR-directed therapies, resulting in …

… , PCa-tumor samples from dogs are often androgen receptor (… as a model for splice-variant-driven
CRPC is undetermined. … for the therapeutic targeting of these tumor-progenitor cells. …

… androgen receptor (AR) axis-targeting treatments, immunotherapeutics, or therapies targeting
… (PARP) inhibitors and PD-1 inhibitors, are under clinical investigation. With increasing …